We have received text from S. 4987: Pharmaceutical Investment Oversight and Accountability Act. This bill was received on 2026-07-15, and currently has 2 cosponsors.

Here is a short summary of the bill:

This bill would require the Federal Trade Commission (FTC), working with the Treasury Department’s Committee on Foreign Investment in the United States (CFIUS), to produce a report on foreign investment in the U.S. pharmaceutical industry.

What the report would cover

• How dependent the U.S. pharmaceutical supply chain is on foreign manufacturing, and what happens when production is concentrated overseas.

• How foreign investment affects the ability of U.S. companies to make drugs, as well as the raw materials and ingredients used in drugs.

• How foreign investment in DNA sequencing and DNA storage technologies in the U.S. could affect the country’s capacity to do that work, including genome and exome analysis.

Review of past government actions

The report would also have to look back over the 10 fiscal years before the study and count how many CFIUS reviews and investigations involved:

• pharmaceutical and medicine manufacturing in the United States, or

• DNA sequencing or DNA storage activities in the United States.

For each of those cases, the report would include a short description saying whether the deal was approved, blocked, or approved with conditions.

How the report would be used

The FTC would have to complete the report within one year after enactment and then update it every year after that. The agency would also publish an unclassified summary on its website for the public to read. The bill does not itself restrict foreign investment or change approval rules; it mainly creates an oversight and reporting requirement.

Relevant Companies

• PFE — Pfizer, a large pharmaceutical manufacturer that could be affected by greater scrutiny of foreign investment and supply-chain dependence in the industry.

• MRK — Merck, a major drugmaker that could be affected if the report leads to more policy attention on foreign ownership or manufacturing reliance.

• LLY — Eli Lilly, a large U.S. pharmaceutical company that could be indirectly affected by changes in oversight of foreign investment in drug manufacturing.

• AMGN — Amgen, a biotechnology company that could be relevant to the bill’s focus on pharmaceutical production and related technologies.

• ILMN — Illumina, a genomics company that could be affected by increased attention to DNA sequencing technologies and related foreign investment.

• TMO — Thermo Fisher Scientific, which has life sciences and sequencing-related businesses that could be affected by oversight of DNA sequencing and storage technologies.

• DHR — Danaher, through its life sciences and genomics businesses, could be indirectly affected by the bill’s focus on sequencing and related infrastructure.

Senator Elizabeth Warren Bill Proposals

Here are some bills which have recently been proposed by Senator Elizabeth Warren:

• S.4987: Pharmaceutical Investment Oversight and Accountability Act
• S.4986: Mamas First Act
• S.4946: Health and Location Data Protection Act of 2026
• S.4743: AI Bubble Transparency Act
• S.4734: Critical Defense Ownership Review Act
• S.4718: Restore Military Families’ Voices Act

You can track bills proposed by Senator Elizabeth Warren on Quiver Quantitative's politician page for Warren.

Senator Elizabeth Warren Net Worth

Quiver Quantitative estimates that Senator Elizabeth Warren is worth $7.1M, as of July 21st, 2026. This is the 138th highest net worth in Congress, per our live estimates.

Warren has approximately $0 invested in publicly traded assets which Quiver is able to track live.

You can track Senator Elizabeth Warren's net worth on Quiver Quantitative's politician page for Warren.

2030 Massachusetts US Senate Election

There has been approximately $26,410,919 of spending in Massachusetts US Senate elections over the last two years, per our estimates.

Approximately $6,796,643 of this has been from outside spending by PACs and Super PACs. Some of the groups who are spending money in this race include:

• COMMONWEALTH UNITY FUND ($4,162,550)
• ADVANCE PROGRESS ($1,482,274)
• COMMONWEALTH TOGETHER PAC ($1,148,679)
• CHINESE PROGRESSIVE POLITICAL ACTION INC. ($1,610)
• UNITED DEMOCRATS FUND ($1,180)

The rating for this race is currently "Solid D".

You can track this election on our matchup page for the 2030 Massachusetts US Senate election.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Read full article here »